Combination ART: are two drugs as good as three?

Affiliations

¹ Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5112, Australia; Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Electronic address: mark.boyd@adelaide.edu.au.
² Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

Comment

Mark A Boyd et al. Lancet. 2018.

. 2018 Mar 3;391(10123):817-819.

doi: 10.1016/S0140-6736(18)30008-4. Epub 2018 Jan 6.

¹ Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5112, Australia; Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Electronic address: mark.boyd@adelaide.edu.au.
² Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

No abstract available

Comment on

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Llibre JM, et al. Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6. Lancet. 2018. PMID: 29310899 Clinical Trial.